<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01867697</url>
  </required_header>
  <id_info>
    <org_study_id>Nordic 8</org_study_id>
    <nct_id>NCT01867697</nct_id>
  </id_info>
  <brief_title>Nordic 8 - A Phase II Trial</brief_title>
  <official_title>Potentially Resectable Metastatic Colorectal Cancer With Wild-type KRAS and BRAF: Alternating Chemotherapy Plus Cetuximab - A Randomised Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Per Pfeiffer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono International SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nordic randomized phase II trial which evaluates whether biweekly cetuximab with alternating
      FOLFIRI and mFOLFOX6 is more effective than biweekly cetuximab with continuously FOLFIRI in
      patients with potential resectable KRAS wildtype metastatic colorectal cancer.

      All patients will be randomized to biweekly cetuximab 500 mg/m2 in combination with arm A)
      FOLFIRI (irinotecan 180 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46
      hours 5FU infusion of 2400 mg/m2 every 2 weeks) or arm B) FOLFIRI alternating with FOLFOX6
      (Oxaliplatin: 85 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU
      infusion of 2400 mg/m2 every 2 weeks) .

      Primary objective: response rate (RECIST 1.1) in patients with with potential resectable KRAS
      wildtype metastatic colorectal cancer.

      Secondary objectives: Resection rate, PFS, OS, Quality of life, tolerability. Biomarker
      evaluation to measure plasma biomarkers, Tumour blocks and sequential serum and plasma will
      be collected to search for markers that may predict efficacy including respectability and
      safety.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (RR)</measure>
    <time_frame>March 2015 (up to 3 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival (Overall survival)</measure>
    <time_frame>June 2016 (up to 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of secondary surgical resection (R0 + R1 + R2 resections)</measure>
    <time_frame>January 2015 (up to 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of secondary micro-radical surgical resection (R0 resection)</measure>
    <time_frame>March 2015 (up to 3 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Biweekly cetuximab with continuously FOLFIRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biweekly cetuximab 500 mg/m2 in combination with FOLFIRI (irinotecan 180 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biweekly cetuximab 500 mg/m2 in combination with FOLFIRI alternating with FOLFOX6 (Oxaliplatin: 85 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <arm_group_label>Biweekly cetuximab with continuously FOLFIRI</arm_group_label>
    <arm_group_label>Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>Biweekly cetuximab with continuously FOLFIRI</arm_group_label>
    <arm_group_label>Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <arm_group_label>Biweekly cetuximab with continuously FOLFIRI</arm_group_label>
    <arm_group_label>Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Carbonate</intervention_name>
    <arm_group_label>Biweekly cetuximab with continuously FOLFIRI</arm_group_label>
    <arm_group_label>Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Histology and stages:

          -  Histologically proven adenocarcinoma in the colon or rectum

          -  At least 1 measurable metastatic disease manifestation according to the RECIST
             criteria (version 1.1)

          -  Potentially completely resectable or potentially curable metastatic colorectal cancer
             as determined by the local MDT conference and that requires tumour shrinkage before
             resection is possible. The following definitions are indicative:

               -  4 or more liver metastases (CRLeM) without extra-hepatic disease

               -  2 or more lung metastases (CRLuM) without hepatic or extra-hepatic disease

               -  1 or more CRLeM determined as &quot;potentially resectable&quot; (such as because of
                  location) by the local MDT.

               -  1 or more CRLuM determined by the local MDT as potentially resectable (such as
                  because of location).

               -  Non-resectable primary disease with resectable CRLeM or CRLuM.

        KRAS and BRAF status:

        - Tumour tissue (primary or metastasis) typed as wild-type KRAS AND wild-type BRAF

        General conditions:

          -  age &gt; 18 years

          -  WHO performance status ≤ 1

          -  expected survival &gt; 3 months

          -  sufficient bone-marrow function (Hb ≥ 6.2 µmol/l/Hb &gt; 10 g/dl ANC ≥ 1.5 x 109/l,
             thrombocytes ≥ 100 x 109/l)

          -  sufficient kidney and liver function: total bilirubin ≤ 1.5 x upper normal limit,
             serum creatinine ≤ 1.25 x upper normal limit, ALAT ≤ 3 x upper normal limit and ≤ 5 x
             upper normal limit with liver metastases

          -  the patient must have signed an informed declaration of consent before being
             registered; this must be documentable according to national guidelines

        Exclusion Criteria:

        Previous treatment:

          -  previous chemotherapy for advanced/metastatic disease

          -  adjuvant chemotherapy unless completed more than 6 months before registration

          -  previous treatment with oxaliplatin or irinotecan

          -  previous treatment with cetuximab or other treatment for EGFR

          -  History of Inflammatory Bowel disease

          -  Severe or uncontrolled cardiovascular disease, congestive heart failure NYHA III or
             IV, unstable angina pectoris, history of myocardial infarction within the last twelve
             months, significant arrhythmias)

          -  Any condition that, according to the treating physician's judgement, could prevent the
             planned medical/surgical treatment from being carried out responsibly (such as
             uncontrolled active infection, known hypersensitivity or contra-indication for the
             planned treatment.

          -  Pregnant or breast-feeding women

          -  Patients of fertile age who do not want to use reliable contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Pfeiffer, Professor, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Halfdan Sørbye, Professor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bengt Glimelius, Professor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Akademiske Sygehus, Uppsala University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Per Pfeiffer, Professor</last_name>
    <phone>+45 6541 1590</phone>
    <email>per.pfeiffer@ouh.regionsyddanmark.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Camilla Qvortrup, MD, PhD</last_name>
    <phone>+45 6541 4852</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mette Yilmaz, MD</last_name>
      <email>m.yilmaz@rn.dk</email>
    </contact>
    <investigator>
      <last_name>Mette Yilmaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Flemming Hansen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Flemming Hansen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lone Noergaard, MD</last_name>
      <email>lone.noergaard.petersen@rh.regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Lone Noergaard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Noerregaard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sydvestjysk Hospital</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brita Bjerregaard, MD</last_name>
      <email>Brita.Bjerregaard.Jensen@svs.regionsyddanmark.dk</email>
    </contact>
    <investigator>
      <last_name>Brita Bjerregaard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herlev University Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benny V Jensen, MD</last_name>
      <email>'BEVI@heh.regionh.dk'</email>
    </contact>
    <investigator>
      <last_name>Benny V Jensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herning Hospital</name>
      <address>
        <city>Herning</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nina Keldsen, MD</last_name>
      <email>nina.keldsen@vest.rm.dk</email>
    </contact>
    <investigator>
      <last_name>Nina Keldsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Naestved Hospital</name>
      <address>
        <city>Naestved</city>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Niels Holländer, MD</last_name>
      <email>nhho@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Niels Holländer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Pfeiffer, Professor</last_name>
      <phone>+45 6541 1590</phone>
      <email>per.pfeiffer@ouh.regionsyddanmark.dk</email>
    </contact>
    <contact_backup>
      <last_name>Camilla Qvortrup, MD, PhD</last_name>
      <phone>+45 6541 4852</phone>
      <email>camilla.qvortrup@ouh.regionsyddanmark.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Per Pfeiffer, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camilla Qvortrup, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henning Overgaard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roskilde Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jim Larsen, MD</last_name>
      <email>jsla@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Jim Larsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Halfdan Sørbye, Professor</last_name>
      <email>halfdan.sorbye@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>Halfdan Sørbye, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trondheim University Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eva Hofsli, MD</last_name>
      <email>Eva.Hofsli@stolav.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akademiska University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bengt Glimelius, Professor</last_name>
      <email>bengt.glimelius@onkologi.uu.se</email>
    </contact>
    <investigator>
      <last_name>Bengt Glimelius, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2012</study_first_submitted>
  <study_first_submitted_qc>June 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2013</study_first_posted>
  <last_update_submitted>January 20, 2015</last_update_submitted>
  <last_update_submitted_qc>January 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Per Pfeiffer</investigator_full_name>
    <investigator_title>Professor, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

